Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Churg-Strauss Syndrome

Thursday, September 14, 2000 - Friday, September 15, 2000
NIH Campus, Bethesda, MD

Churg-Strauss syndrome is a rare disease that is characterized by hypereosinophilia and vasculitis. Since the approval in 1996 of the new anti-leukotriene therapy for asthma, several new cases of Churg-Strauss syndrome have been diagnosed. It is not clear whether these cases are the result of an untoward effect of anti-leukotriene therapy or a primary eosinophilic disease that had been incorrectly diagnosed and treated as asthma. Several published reports suggest that the anti-leukotriene therapy allowed a reduction in corticosteroid therapy for asthma and thus unmasked the underlying condition of Churg-Strauss syndrome. This workshop explored the nature and magnitude of the association between anti-leukotriene therapy and Churg-Strauss syndrome and identified priorities for research into the pathogenesis of eosinophilic syndromes. Many of the scientific and therapeutic questions raised by the reports of Churg-Strauss syndrome being recognized in patients receiving anti-leukotriene therapy were addressed. The NIH workshop report on the relationship of asthma therapy and Churg-Strauss syndrome was published in the Journal of Allergy and Clinical Immunology in FY 2001.

Dr. Marshall Plaut (301) 496-8973
Dr. Virginia Taggart (301) 435-0202

Co-funding Institute(s):
National Heart, Lung, and Blood Institute

From the National Center for Advancing Translational Sciences

From the National Institutes of Health

Connect with ORDR

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.